Startup profile · funding coverage
Traitomic funding, valuation and investors
Carlsberg-origin plant and microbial trait discovery business using FIND-IT to select genetic variants without direct genome editing.
Verified company research · funding, investors and latest developments
Keep track of Traitomic
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
€20M · November 17, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Copenhagen, Denmark
Investors in latest funding
Lead: Sofinnova Partners
Other: Export and Investment Fund of Denmark (EIFO) , Footprint Firm , PSV Hafnium , Nordic Foodtech VC , SVG Ventures
Overview
Traitomic commercializes FIND-IT, a targeted genetic-variation and screening process developed at Carlsberg Research Laboratory. It supports crop and microorganism customers seeking specific useful traits through conventional-breeding approaches. It selects and validates variants in genetic libraries, then hands over relevant biological material and information for further development.
Contract prices, development cycles, per-trait economics, regulatory status by geography and valuation are undisclosed.
Why Traitomic is interesting
A €20M Series A led by Sofinnova on November 17 funds a non-GM route to valuable plant and microbial variants, with biological material delivery to customers rather than a consumer seed marketplace. The financier and deal adviser corroborate its first external financing.
Product & use cases
Representative customer engagement described in Traitomic's own guide: (1) a breeder or biotech producer defines a desired outcome and source organism; (2) scientists agree a Traitomic Plan of Approach and whether to use customer biological material or an established library; (3) FIND-IT identifies targeted variants through a controlled-variation and screening process; (4) Traitomic isolates promising seeds, plants or strains; (5) partners evaluate the genetic change and phenotype against commercial objectives; (6) genetic information and biological material are transferred for customer's own validation, scale-up and commercialization. This is a sourced process description, not independent testing or a claim all projects achieve the target.
- Plant breeders: find naturally occurring variants associated with desired agronomic or quality traits.
- Food and fermentation firms: select microbial strains with targeted production properties.
- Industrial biotech companies: screen organisms before later scale-up and regulatory checks.
Key facts
- €20M Series A disclosed 17 November 2026, led by Sofinnova Partners with EIFO, Footprint Firm, PSV Hafnium, Nordic Foodtech VC and SVG Ventures participating.
- ABG Sundal Collier says it advised Carlsberg Group on the transaction, corroborating the issuer's disclosure.
- Company materials describe targeted genetic screening, isolation and biological-material transfer—not CRISPR editing of customer varieties.
- Third-party coverage reports 116 traits delivered to 47 customers across 32 organisms; these remain reported operating metrics, not audited revenue or successful downstream market launches.
- Traitomic originated from Carlsberg's breeding research; separate Carlsberg brewing IP and licence scope should not be inferred beyond public statements.
Funding history (newest first)
Series A
2026-11-17 €20M- Sofinnova Partners (lead)
- Export and Investment Fund of Denmark (EIFO) (participant)
- Footprint Firm (participant)
- PSV Hafnium (participant)
- Nordic Foodtech VC (participant)
- SVG Ventures (participant)
Source: Read source · abgsc.com
Investors in our directory
Funds linked from Traitomic's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Potentially useful for companies seeking trait discovery without directly engineering the final genome; however, regulation of novel varieties and microorganisms differs by jurisdiction and production pathway. The vendor has not published a universal time-to-trait, success rate, customer ROI or per-project price.
Procurement should compare target genetic variants found, validated phenotype, time to breed into production material, freedom to operate and licensing/ownership of strains. Vendor-reported delivered trait counts do not reveal downstream commercial adoption or regulatory clearance.
-
KeyGene direct
Plant genomics and breeding technology specialist; compare trait discovery and breeding services.
-
Inari Agriculture adjacent
Gene-editing-led seed improvement; fundamentally different regulatory and IP tradeoffs.
-
Pairwise adjacent
CRISPR-enabled crop trait development; compare desired trait and go-to-market pathway.
-
In-house mutagenesis and screening alternative
Traditional in-house R&D may offer greater IP control with higher lab capacity needs.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Traitomic
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.